References
- Data on SARS-CoV-2 pandemic worldwide provided by the World Health
Organization
https://www.who.int/docs/default-source/coronaviruse/transcripts/who-audio-emergencies-coronavirus-press-conference-full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2
- Wollenberg A, Flohr C, Simon D, et al. European Task Force on Atopic
Dermatitis statement on severe acute respiratory syndrome coronavirus
2 (SARS-Cov-2) infection and atopic dermatitis. J Eur Acad Dermatol
Venereol 2020; 34: e241-e242.
- Vultaggio A, Agache I, Akdis CA, et al. Considerations on biologicals
for patients with allergic disease in times of the COVID-19 pandemic:
an EAACI Statement [published online ahead of print, 2020 Jun 5].
Allergy. 2020; 10.1111/all.14407.
- National Recommendations by the Italian Society of Dermatology
https://www.sidemast.org/blog/coronavirus
- Shah M, Sachdeva M, Alavi A, Shi VY, Hsiao JL. Optimizing care for
atopic dermatitis patients during the COVID-19 pandemic. J Am Acad
Dermatol. 2020; 8: e165-e167.
- Giuliani F, Gualdi G, Amerio P. Effect of immunosuppressive drugs in
immune-mediated inflammatory disease during the coronavirus pandemic.
Dermatol Ther. 2020: e14204.
- Kearns DG, Uppal S, Chat VS, Wu JJ. Assessing the risk of dupilumab
use for atopic dermatitis during the COVID-19 pandemic. J Am Acad
Dermatol. 2020; 83: e251-e252.
- Data related to COVID-19 pandemic in Italy
http://opendatadpc.maps.arcgis.com/apps/opsdashboard/index.html#/b0c68bce2cce478eaac82fe38d4138b1
- Napolitano M, Patruno C, Ruggiero A, Nocerino M, Fabbrocini G. Safety
of dupilumab in atopic patients during COVID-19 outbreak. J Dermatolog
Treat. 2020;1-2.
- Ferrucci S, Romagnuolo M, Angileri L, Berti E, Tavecchio S. Safety of
dupilumab in severe atopic dermatitis and infection of Covid-19: two
case reports. J Eur Acad Dermatol Venereol. 2020;34: e303-e304.
- Caroppo F, Biolo G, Belloni Fortina A. SARS-CoV-2 asymptomatic
infection in a patient under treatment with dupilumab. J Eur Acad
Dermatol Venereol. 2020;34: e368.
- Carugno A, Raponi F, Locatelli AG, Vezzoli P, Gambini DM, Di Mercurio
M, et al. No evidence of increased risk for COVID-19 infection in
patients treated with Dupilumab for atopic dermatitis in a
high-epidemic area - Bergamo, Lombardy, Italy. J Eur Acad Dermatol
Venereol 2020 Apr 27;10.1111/jdv.16552.
- Eichenfield LF, Bieber T, Beck LA, Simpson EL, Thaçi D, de
Bruin-Weller M, et al. Infections in dupilumab clinical trials in
atopic dermatitis: a comprehensive pooled analysis. Am J Clin
Dermatol. 2019;20:443-456.
- Worm M, Simpson EL, Thaçi D, Bissonnette R, Lacour JP, Beissert S, et
al. Efficacy and safety of multiple dupilumab dose regimens after
initial successful treatment in patients with atopic dermatitis: a
randomized clinical trial. JAMA Dermatol. 2020;156:131-143.
- Pirro F, Caldarola G, Chiricozzi A, Tambone S, Mariani M, Calabrese L,
et al. The impact of COVID-19 pandemic in a cohort of Italian
psoriatic patients treated with biological therapies. J Dermatolog
Treat. 2020:1-5.
- Dyrberg Loft N, Halling AS, Iversen L, Vestergaard C, Deleuran M,
Kirchheiner Rasmussen M, et al. Concerns related to the COVID-19
pandemic in adult patients with atopic dermatitis and psoriasis
treated with systemic immunomodulatory therapy: a Danish questionnaire
survey. J Eur Acad Dermatol Venereol. 2020;10.1111/jdv.16863.
- Mahil SK, Yiu ZZN, Mason KJ, Dand N, Coker B, Wall D, et al. Global
reporting of cases of COVID-19 in psoriasis and atopic dermatitis: an
opportunity to inform care during a pandemic. Br J Dermatol. 2020;
183:404-406.